清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract A098: Quantitative MRI metrics capture pancreatic cancer and stroma responses to novel KRAS inhibitor

作者
Mamta Gupta,Hoon Choi,Emma Elizabeth Furth,Miguel Romanello Joaquim,Stephen Pickup,Cynthia Clendenin,Margo Orlen,Thomas Benjamin Karasic,Hee Kwon Song,Yong Fan A,Peter James O'Dwyer,Robert H. Vonderheide,Mark Alan Rosen,Ben Z. Stanger,Rong Zhou
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (2_Supplement): A098-A098
标识
DOI:10.1158/1538-7445.panca2023-a098
摘要

Abstract Introduction Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer with limited treatment options. Oncogene KRAS mutations found in majority of PDA patients with KRAS(G12D) mutation being the most common. A new KRAS(G12D) specific inhibitor, MRTX1133 has been shown to induce rapid tumor regression in PDA models while the effect on stroma is only revealed by postmortem analyses of tumor specimens, making it hard to assess the dynamics of stroma remodeling. Furthermore, in clinical testing of KRAS(G12C) inhibitor, only ~50% of patients responded to the treatment despite the presence of correct genetic mutation in biopsy specimens, therefore, early and accurate assessment of the drug-target engagement is important in clinical setting. Our study was designed to test the hypothesis that multimetric MRI captures early responses to KRAS(G12D) inhibitor beyond the change of tumor size in a PDA model. Especially, changes in apparent diffusion coefficient (ADC) from diffusion weighted (DW) MRI, Ktrans from dynamic contrast enhanced (DCE) MRI, and magnetization transfer ratio (MTR). Methods A genetically engineered model of PDA bearing KRAS(G12D) and Trp53 mutation referred to as KPC was used. Male and female mice were enrolled to receive MRTX1133 at 30mg/kg BID or PBS via i.p injection. Murine PDA cells bearing KRAS(G12C) mutation were inoculated in the flank of C57BL/6 mice to grow subcutaneous tumors. In vivo DW- and DCE-MRI were obtained on a 9.4T Bruker system employing pulse sequences insensitive to respiratory motion. Results In KPC mice, striking increase of tumor ADC were detected as early as 48h after treatment initiation and was confirmed by statistical analyses at 48h and day7 accompanied by decrease of tumor size, in contrast to a trend of increased tumor size and decreased ADC in PBS-treated mice. H&E section revealed gross necrosis and extensive cell death. A clear increase of Ktrans suggesting an increase of capillary permeability and/or perfusion was detected at 48h, persisting to day7; while CD31 did not change significantly, capillary lumen area appeared enlarged at 48h, consistent with reduced interstitial fluid pressure resulted from clearance of stromal hyaluronic acid. A remarkable reduction of MTR at 48h clearly captured the stromal effect of MRTX1133 whereas no change observed in PBS-treated mice. Consistently, Sirius red (SR) staining for collagen revealed a high degree of heterogeneity where regions of depletion versus dense SR staining coexist. Lack of tumor regression and ADC change in KRAS(G12C) tumors confirmed the specificity of MRTX1133 to G12D however, a reduction of MTR was revealed, suggesting stromal impact as off-target effect of MRTX1133. Conclusion To our knowledge, this represents the first MRI study of the new KRAS inhibitor. The multimetric MRI approach is novel and significant because it captured MRTX1133-induced cancer cell death and stroma change over time. With further validation, these translatable imaging metrics can provide biological mechanism underneath tumor size change in the clinical setting. Citation Format: Mamta Gupta, Hoon Choi, Emma E. Furth, Miguel Joaquim, Stephen Pickup, Cynthia Clendenin, Margo Orlen, Thomas Karasic, Hee Kwon Song, Yong Fan, Peter O’Dwyer, Robert H. Vonderheide, Mark Rosen, Ben Z. Stanger, Rong Zhou. Quantitative MRI metrics capture pancreatic cancer and stroma responses to novel KRAS inhibitor [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr A098.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
懒得起名字完成签到 ,获得积分10
4秒前
温暖的胜完成签到,获得积分10
10秒前
无悔完成签到 ,获得积分0
23秒前
纯真的雁凡完成签到,获得积分10
25秒前
柔弱的铅笔完成签到,获得积分10
27秒前
Tracy发布了新的文献求助10
33秒前
38秒前
顺利夏云完成签到,获得积分10
51秒前
xingsixs发布了新的文献求助10
52秒前
Tracy完成签到,获得积分10
57秒前
zwlei完成签到,获得积分10
1分钟前
腼腆的雪珊完成签到,获得积分10
1分钟前
热情的衬衫完成签到,获得积分10
1分钟前
xingsixs完成签到,获得积分10
1分钟前
危机的白凡完成签到,获得积分10
1分钟前
徐伟业完成签到 ,获得积分10
1分钟前
RetchieLi完成签到,获得积分10
1分钟前
1分钟前
无限幻枫发布了新的文献求助10
1分钟前
眼睛大的向彤完成签到,获得积分10
1分钟前
俭朴映寒完成签到,获得积分10
1分钟前
汉堡包的应助被bluemoon采纳,获得10
1分钟前
1分钟前
王磊磊0811发布了新的文献求助10
2分钟前
害羞傲安完成签到,获得积分10
2分钟前
外向夜阑完成签到,获得积分10
2分钟前
LINDENG2004完成签到 ,获得积分10
2分钟前
年轻千萍完成签到,获得积分10
2分钟前
睡不醒完成签到 ,获得积分10
2分钟前
简单的不平完成签到,获得积分10
2分钟前
一个爱打乒乓球的彪完成签到 ,获得积分10
3分钟前
单身的涫完成签到,获得积分10
3分钟前
闪闪小凡完成签到,获得积分10
3分钟前
孝顺的冰姬完成签到,获得积分10
3分钟前
拼搏愚志完成签到,获得积分10
3分钟前
田田完成签到 ,获得积分10
3分钟前
无情幻巧完成签到,获得积分10
3分钟前
Lucas的应助被科研通管家采纳,获得10
3分钟前
3分钟前
Alvin完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158937
求助须知:如何正确求助?哪些是违规求助? 9554526
关于积分的说明 21719385
捐赠科研通 7748487
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552013
邀请新用户注册赠送积分活动 2471370